

Resource Summary Report

Generated by [ASWG](#) on Aug 2, 2026

survminer

RRID:SCR_021094

Type: Tool

Proper Citation

survminer (RRID:SCR_021094)

Resource Information

URL: <https://rdocumentation.org/packages/survminer/versions/0.4.9>

Proper Citation: survminer (RRID:SCR_021094)

Description: Software R package provides functions for facilitating survival analysis and visualization.

Resource Type: data visualization software, data analysis software, software application, software resource, data processing software

Keywords: survival analysis, survival visualization, R

Availability: Free, Available for download, Freely available

Resource Name: survminer

Resource ID: SCR_021094

License: GPL-2

Record Creation Time: 20220129T080353+0000

Record Last Update: 20260801T190712+0000

Ratings and Alerts

No rating or validation information has been found for survminer.

No alerts have been found for survminer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 92 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Chang LJ, et al. (2026) Assessment of Circulating Tumor DNA for Early Detection of Hepatocellular Carcinoma in Alpha-Fetoprotein-Negative Patients With Cirrhotic Nodules. JGH open : an open access journal of gastroenterology and hepatology, 10(1), e70331.

Wu Z, et al. (2025) A dual-targeting strategy to inhibit colorectal cancer liver metastasis via tumor cell ferroptosis and cancer-associated fibroblast reprogramming. Bioactive materials, 52, 73.

Tedeschi A, et al. (2025) Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification. Molecular cancer therapeutics, 24(4), 550.

Michel M, et al. (2025) Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(7), 1275.

Negrao MV, et al. (2025) Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(6), 1069.

Egea-Rodriguez S, et al. (2025) RECQL4 affects MHC class II-mediated signalling and favours an immune-evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma. Clinical and translational medicine, 15(1), e70094.

Lakbir S, et al. (2025) Tumor break load quantitates structural variant-associated genomic instability with biological and clinical relevance across cancers. NPJ precision oncology, 9(1), 140.

Krishnan T, et al. (2025) Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors. Cancer research communications, 5(1), 66.

Mazambani S, et al. (2025) Targeting the Glucose-Insulin Link in Head and Neck Squamous Cell Carcinoma Induces Cytotoxic Oxidative Stress and Inhibits Cancer Growth. Cancer research communications, 5(6), 921.

Mayer M, et al. (2025) Deciphering the cellular tumor microenvironment landscape in salivary gland carcinomas using multiplexed imaging mass cytometry. Journal of experimental & clinical cancer research : CR, 44(1), 288.

Embaie BT, et al. (2025) Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State. Cancer research, 85(6), 1015.

Labaf M, et al. (2025) Heterogeneous Responses to High-Dose Testosterone in Castration-Resistant Prostate Cancer Tumors with Mixed Rb-Proficient and Rb-Deficient Cells. *Molecular cancer therapeutics*, 24(5), 772.

Chiang AC, et al. (2025) Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents. *JTO clinical and research reports*, 6(9), 100829.

Hu Q, et al. (2025) Circulating tumor DNA monitoring detects minimal residual disease and predicts outcomes in patients with esophageal adenocarcinoma or squamous cell carcinoma after esophagectomy. *BJC reports*, 3(1), 52.

Scheurlen KM, et al. (2025) Itaconate and obesity-related hormones promote tumor progression - new insights on metabolic dysfunction in early-onset colon cancer. *Frontiers in immunology*, 16, 1572985.

Mout L, et al. (2025) Genetic and Epigenetic Reprogramming of Transposable Elements Drives ecDNA-Mediated Metastatic Prostate Cancer. *bioRxiv : the preprint server for biology*.

Young AA, et al. (2025) PACT suppresses PKR activation through dsRNA binding and dimerization, and is a therapeutic target for triple-negative breast cancer. *RNA (New York, N.Y.)*, 31(11), 1599.

Jin D, et al. (2025) Unveiling the prognostic and immunological role of IFI44 in glioma. *Annals of medicine*, 57(1), 2593209.

Xia Y, et al. (2025) Therapeutic Potential of STE20-Type Kinase STK25 Inhibition for the Prevention and Treatment of Metabolically Induced Hepatocellular Carcinoma. *Cellular and molecular gastroenterology and hepatology*, 19(7), 101485.

Xia J, et al. (2025) BDNF is a prognostic biomarker involved in the immune infiltration of lung adenocarcinoma and associated with programmed cell death. *Oncology letters*, 29(4), 191.